(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 25.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Codexis's revenue in 2025 is $59,345,000.On average, 4 Wall Street analysts forecast CDXS's revenue for 2025 to be $5,445,724,825, with the lowest CDXS revenue forecast at $5,400,992,677, and the highest CDXS revenue forecast at $5,508,681,182. On average, 4 Wall Street analysts forecast CDXS's revenue for 2026 to be $6,623,671,388, with the lowest CDXS revenue forecast at $6,179,663,401, and the highest CDXS revenue forecast at $7,781,736,995.
In 2027, CDXS is forecast to generate $11,409,182,844 in revenue, with the lowest revenue forecast at $11,409,182,844 and the highest revenue forecast at $11,409,182,844.